What is TechsoMed?
TechsoMed is a specialized medical technology firm focused on the development of the BioTrace platform. This innovative software solution integrates seamlessly with standard commercial ultrasound imaging equipment to provide physicians with real-time, AI-driven insights into tissue viability. By enabling precise visualization during thermal ablation, the platform serves a diverse range of high-stakes clinical applications, including oncology for tumor ablation, cardiology for heart arrhythmia treatment, and pain management through radiofrequency neurotomy. The company's market position is defined by its ability to enhance existing hardware infrastructure with sophisticated software intelligence, thereby improving patient outcomes without requiring costly new diagnostic equipment.
How much funding has TechsoMed raised?
TechsoMed has raised a total of $9.6M across 2 funding rounds:
Other Financing Round
$2.6M
Series B
$7M
Other Financing Round (2019): $2.6M with participation from Axil Capital, Screen Holdings, JJDC, NextLeap Ventures, and AMIT-Technion
Series B (2021): $7M led by Axil Capital, Cobro Ventures, JJDC, JLABS companies, Radianx Capital, NextLeap Ventures, Magna Capital Partners, and Yonjin Venture
Key Investors in TechsoMed
JJDC
Johnson & Johnson is a global healthcare company that develops pharmaceuticals and medical technologies. It provides innovative medicines, surgical products, and medical devices used in areas such as oncology, immunology, neuroscience, and cardiovascular care, serving healthcare providers and patients worldwide.
Magna Capital Partners
Magna Capital Partners is a collaborative and forward-looking investment firm that prioritizes ethical standards and value creation. They focus on building long-term partnerships with businesses to achieve optimal growth and strategic success.
Axil Capital
Axil Capital is a venture investment firm that provides strategic backing to innovative companies, often focusing on high-growth sectors within the technology and healthcare landscapes.
What's next for TechsoMed?
With the recent influx of capital, TechsoMed is poised to expand its clinical footprint and refine its algorithmic capabilities. The strategic roadmap likely involves deepening the integration of the BioTrace platform across global healthcare systems, particularly in oncology and cardiology departments where real-time imaging is paramount. As the company scales, it will likely focus on securing additional regulatory clearances and fostering partnerships with major medical device manufacturers to broaden the reach of its AI-driven diagnostic tools. The focus remains on maintaining a competitive edge in the medical imaging software market by continuously iterating on its core technology to meet the evolving demands of precision medicine.
See full TechsoMed company page
